Abstract
There is no standard treatment for patients with locally advanced gastric cancer (LAGC). Neoadjuvant immunochemotherapy (NICT) is an emerging therapeutic strategy in LAGC. The prognosis of patients undergoing NICT plus radical surgery varies. Hypercoagulation is frequently identified in cancer patients. A retrospective study by Li et al confirmed that in LAGC patients undergoing radical resection post-NICT, elevated D-dimer and fibrinogen levels were associated with poor prognosis, and their combined assessment improved predictive accuracy. This retrospective study has some limitations, and further prospective research is required to validate hypercoagulation as a prognostic indicator and develop a more precise predictive model. Establishing such a model can facilitate personalized treatment strategies for patients with LAGC.